Search results for " THERAPY"

showing 10 items of 9467 documents

Acute Necrotic Plaque in an Immunocompromised Host.

2017

0301 basic medicineMalePathologymedicine.medical_specialtyNecrosisAntifungal Agentsmedicine.medical_treatment030106 microbiologyGraft vs Host DiseaseDermatologyHematopoietic stem cell transplantationOpportunistic InfectionsRisk AssessmentPathology and Forensic Medicine03 medical and health sciencesImmunocompromised HostNecrosismedicineHumansMucormycosisbusiness.industryHost (biology)MucormycosisBiopsy NeedleHematopoietic Stem Cell TransplantationGeneral MedicineMiddle Agedmedicine.diseasePrognosisImmunohistochemistryAcute DiseaseDrug Therapy Combinationmedicine.symptomEpidermisbusinessThe American Journal of dermatopathology
researchProduct

The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer

2019

Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) may prospectively decrease absolute lean mass (LM) and increase absolute fat mass (FM). Given that estimates of LM by dual‐energy X‐ray absorptiometry may be overestimated in obese people, this study examined the influence of adiposity on muscle health in men treated with ADT for PCa. Methods: This cross‐sectional study examined the influence of adiposity on total and appendicular LM (ALM), muscle cross‐sectional (CSA), and muscle strength in 70 men treated with ADT [mean (standard deviation) age, 71 (6) years] for PCa compared with age‐matched PCa (n = 52) and healthy controls (n = 70). Total body LM, FM and ALM, and …

0301 basic medicineMaleSarcopenialcsh:Diseases of the musculoskeletal systemBody compositionprostatic neoplasmsBody Mass IndexAndrogen deprivation therapyProstate cancer0302 clinical medicineAbsorptiometry PhotonMedicineOrthopedics and Sports MedicineQuantitative computed tomographyAdipositymedicine.diagnostic_testeturauhassyöpäOrgan Sizelcsh:Human anatomyMiddle Agedadipose tissue030220 oncology & carcinogenesissyöpätauditOriginal ArticleProstatic neoplasmsmedicine.medical_specialtymedicine.drug_classUrologyrasvakudoksetAdipose tissuelcsh:QM1-695sarcopenia03 medical and health sciencesAtrophyPhysiology (medical)HumansMuscle SkeletalatrofiakehonkoostumusAgedbusiness.industryAndrogen AntagonistsOriginal Articlesmedicine.diseaseAndrogen030104 developmental biologyCross-Sectional StudiesSarcopeniaLean body massAtrophylcsh:RC925-935businessBody mass indexlihassurkastumasairaudetBiomarkersJournal of Cachexia, Sarcopenia and Muscle
researchProduct

Effects of transcranial random noise stimulation combined with Graded Repetitive Arm Supplementary Program (GRASP) on motor rehabilitation of the upp…

2019

We evaluated the combined use of transcranial random noise stimulation (tRNS) with the Graded Repetitive Arm Supplementary Program (GRASP) in sub-acute ischemic stroke patients suffering from arm impairment. Eighteen ischemic stroke patients with upper limb disability were randomly assigned to either the GRASP + tRNS or GRASP + Sham stimulation group. Fugl-Meyer Assessment-Upper extremity (FMA-UE) was performed to evaluate upper limb impairment before treatment (T0), after the last stimulation (T1) and after 30 days (T2). At T1 and T2, beneficial effects in the tRNS group correlated with better FMA-UE score than sham stimulation group (p < 0.001) and these results did not correlate to st…

0301 basic medicineMaleStroke rehabilitationmedicine.medical_specialtyNeurologyStimulationPilot ProjectsSub acuteTranscranial Direct Current StimulationUpper Extremity03 medical and health sciencesTranscranial random noise stimulation0302 clinical medicinePhysical medicine and rehabilitationDouble-Blind MethodmedicineHumansGraded Repetitive Arm Supplementary Program (Grasp)Biological PsychiatryPhysical Therapy ModalitiesAgedbusiness.industryGRASPTranscranial random noise stimulation combined (tRNS)BrainRecovery of FunctionCombined Modality TherapyMotor rehabilitationPsychiatry and Mental health030104 developmental biologymedicine.anatomical_structureTreatment OutcomeNeurologyIschemic strokeUpper limbFemaleSettore MED/26 - NeurologiaNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Dietary intake in population with metabolic syndrome: is the prevalence of inadequate intake influenced by geographical area? cross-sectional analysi…

2018

Inadequate diet influences chronic diseases such as cardiovascular disease (CVD), the leading cause of death in Spain. CVD figures vary from one geographical region to another

0301 basic medicineMaleSíndrome metabòlicacumplimiento del pacienteCross-sectional studyhumanosejercicio físicoOverweightDiet MediterraneanRecommended Dietary AllowancesgeografíaNutrientClinical trialsSurveys and QuestionnairesFood choicePrevalenceMedicineMicronutrientsmediana edadDietoteràpiaRandomized Controlled Trials as Topic2. Zero hungereducation.field_of_studyancianoNutrition and DieteticssobrepesoGeographydietaensayos clínicos controlados aleatorizados como asuntoprevalenciaPREDIMED-Plus studyMiddle AgedMetabolic syndrome3. Good healthestado nutricionalDietary Reference IntakePlace of residenceFemalemedicine.symptomevaluación nutricionalcantidad dietética recomendadageographical arealcsh:Nutrition. Foods and food supplynutrient adequacyPopulationNutritional Statuslcsh:TX341-641metabolic syndromeArticle03 medical and health sciencesEnvironmental healthHumansplace of residencecardiovascular diseasesObesityeducationobesidadExerciseAgedGeographical area030109 nutrition & dieteticsNutrient adequacybusiness.industryDietary intakeDiet therapymicronutrientesOverweightmedicine.diseaseObesityDietCross-Sectional StudiesNutrition AssessmentSpainPatient ComplianceMetabolic syndromebusinessdietary intakeFood ScienceAssaigs clínicsestudios transversales
researchProduct

Induced post-traumatic apexification: 20 year follow-up and morphological study after new fracture.

2018

Apexification is an endodontic technique used in immature necrotic teeth, the primary goal of which is to induce a calcified barrier in roots with open apices and to promote the continuation of apical root development. A 7-year-old patient with a coronal fracture in a maxillary central incisor was treated with an apexification technique using calcium hydroxide. The apical closure was obtained after one year, then a permanent root canal filling was performed. The tooth was monitored for a period of 20 years, up to when a trauma caused its extraction. The newly formed root was analyzed macroscopically, histologically and through scanning electron microscopy. A morphologically normal root was …

0301 basic medicineMaleTertiary dentineRoot canalDentistryCalcium Hydroxide03 medical and health scienceschemistry.chemical_compoundTooth Fractures0302 clinical medicinestomatognathic systemDental Pulp NecrosisMedicineHumansMaxillary central incisorTooth RootChildDental PulpPulp necrosisCalcium hydroxidebusiness.industryApexification030206 dentistryGeneral MedicineApex (geometry)Root Canal TherapyIncisorstomatognathic diseasesmedicine.anatomical_structurechemistryCoronal planeMicroscopy Electron ScanningApexification030101 anatomy & morphologyAnatomybusinessDevelopmental BiologyFollow-Up StudiesAnnals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
researchProduct

Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients.

2018

AbstractMonitoring the human virome has been recently suggested as a promising and novel area of research for identifying new biomarkers which would help physicians in the management of transplant patients. Imbalance of the immune system in transplant recipients has a significant impact on replication of Torquetenovirus (TTV), the most representative and abundant virus of human virome. TTV kinetic was studied by real-time PCR in 280 liver or kidney transplant recipients who underwent different drug regimens to maintain immunosuppression. During one-year post-transplant follow-up, TTV viremia fluctuated irrespective of transplanted organ type but consistent with the immunosuppression regimen…

0301 basic medicineMaleTime Factorsmedicine.medical_treatmentlcsh:MedicineCytomegalovirusVIROMEPostoperative ComplicationsANELLOVIRUSESlcsh:ScienceKidney transplantationTT VIRUSLUNG TRANSPLANTATIONDNA VIRUSAged 80 and overMultidisciplinaryIMMUNOSUPPRESSIONCMVvirus diseasesImmunosuppressionMiddle AgedViral LoadPrognosissurgical procedures operativeNEXT-GENERATIONCytomegalovirus InfectionsFemaleTORQUE TENO VIRUS; STEM-CELL TRANSPLANTATION; TT VIRUS; LUNG TRANSPLANTATION; NEXT-GENERATION; DNA VIRUS; IMMUNOSUPPRESSION; ANELLOVIRUSES; VIROME; HEPATITISViral loadAdult030106 microbiologyCongenital cytomegalovirus infectionTTVViremiaArticle03 medical and health sciencesHEPATITISYoung AdultmedicineHumansHuman viromeViremiaAgedImmunosuppression TherapyTorque teno virusbusiness.industrylcsh:RTTV; CMV; Transplant patientsSTEM-CELL TRANSPLANTATIONmedicine.diseaseKidney TransplantationTransplant RecipientsTransplantationRegimen030104 developmental biologyImmunologyTransplant patientslcsh:QVirus ActivationbusinessScientific reports
researchProduct

VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection

2016

Congestive heart failure is one of the leading causes of disability in long-term survivors of cancer. The anthracycline antibiotic doxorubicin (DOX) is used to treat a variety of cancers, but its utility is limited by its cumulative cardiotoxicity. As advances in cancer treatment have decreased cancer mortality, DOX-induced cardiomyopathy has become an increasing problem. However, the current means to alleviate the cardiotoxicity of DOX are limited. We considered that vascular endothelial growth factor-B (VEGF-B), which promotes coronary arteriogenesis, physiological cardiac hypertrophy, and ischemia resistance, could be an interesting candidate for prevention of DOX-induced cardiotoxicity …

0301 basic medicineMaleVEGFBVascular Endothelial Growth Factor BAnthracyclineAdipose Tissue WhiteCardiomyopathyheart failureApoptosisheart030204 cardiovascular system & hematologyPharmacologyta3111Mitochondria Heart03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumorNeoplasmsmedicinepolycyclic compoundscancerAnimalsDoxorubicinTube formationCardiotoxicityMultidisciplinaryAntibiotics Antineoplasticbusiness.industryta1184MyocardiumEndothelial CellsGenetic TherapyBiological Sciencesmedicine.diseaseCardiotoxicity3. Good healthVascular endothelial growth factorMice Inbred C57BL030104 developmental biologychemistryLiverDoxorubicinHeart failureendothelial cellArteriogenesisbusinessmedicine.drugDNA Damage
researchProduct

Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.

2017

Efficacy and safety of elosulfase alfa enzyme replacement therapy (ERT) were assessed in an open-label, phase 2, multi-national study in Morquio A patients aged ≥5 years unable to walk ≥30 meters in the 6-min walk test. Patients received elosulfase alfa 2.0 mg/kg/week intravenously for 48 weeks. Efficacy measures were functional dexterity, pinch/grip strength, mobility in a modified timed 25-foot walk, pain, quality of life, respiratory function, and urine keratan sulfate (KS). Safety/tolerability was also assessed. Fifteen patients received elosulfase alfa, three patients discontinued ERT due to adverse events (two were grade 3 drug-related adverse events, the other was not drug-related), …

0301 basic medicineMaleWalkingchemistry.chemical_compoundGrip strengthGALNS protein0302 clinical medicineElosulfase alfaQuality of lifeActivities of Daily LivingRespiratory functionFunctional abilityChildGenetics (clinical)education.field_of_studyMucopolysaccharidosis IVChondroitinsulfatases3. Good healthRespiratory Function TestsTreatment OutcomeTolerability6.1 PharmaceuticalsOriginal ArticleFemalePatient Safetyphysical enduranceGALNS protein human [supplementary concept]Adultsafetymedicine.medical_specialtyAdolescentClinical Trials and Supportive ActivitiesPopulationClinical Sciences03 medical and health sciencesYoung Adultmobility limitationClinical ResearchInternal medicinemedicineGeneticsHumansEnzyme Replacement TherapyAdverse effecteducationhuman [supplementary concept]Exercisebusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articles030104 developmental biologychemistryKeratan SulfateQuality of LifeSelf Reportbusiness030217 neurology & neurosurgeryBiomarkers
researchProduct

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

2018

Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log 10 HIV-1 RNA copies/mL (IQR …

0301 basic medicineMaleantiretroviral therapy; HIV; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Mutation; Odds Ratio; Prevalence; Viral Proteins; Drug Resistance Viralantiretroviral therapy; HIV; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance; Health Policy; Infectious Diseases; Pharmacology (medical)Drug ResistanceHIV InfectionsDrug resistanceGastroenterologyInterquartile rangeOdds RatioPrevalenceHIV InfectionPharmacology (medical)ViralbiologyHealth PolicyMiddle AgedIntegraseInfectious DiseasesItalyFemaleViral loadHumanresistance epidemiologyAdultmedicine.medical_specialtytransmitted HIV drug resistanceAnti-HIV AgentsHIV; antiretroviral therapy; recent HIV infection; resistance epidemiology; transmitted HIV drug resistance030106 microbiologyantiretroviral therapySettore MED/17 - MALATTIE INFETTIVEVirus03 medical and health sciencesrecent HIV infectionViral ProteinsInternal medicineDrug Resistance ViralmedicineViral ProteinHumansbusiness.industryAnti-HIV AgentHIVOdds ratioReverse transcriptaseConfidence intervalCD4 Lymphocyte CountMutationbiology.proteinHIV-1business
researchProduct

Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.

2017

Objective Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity. The aim of this study was to assess the outcomes of pediatric patients with MOGCT. Methods Patients were treated according to their stage: surgery and surveillance for stage I; a modified bleomycin–etoposide–cisplatin (BEP) regimen for stages II (three cycles), III, and IV (three cycles) with surgery on residual disease. Results Seventy-seven patients were enrolled (median age 11.8 years), 26 with dysgerminoma (Dysg), 13 with immature teratoma and elevated serum alpha-fetoprotein levels (IT + AFP), and 38 with nondy…

0301 basic medicineMalechildhood; germ cell tumors; ovarianGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesStage (cooking)germ cell tumorsProspective cohort studyChildEtoposideOvarian NeoplasmsHematologychildhood germ cell tumors ovarianNeoplasms Germ Cell and EmbryonalPrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolFemalemedicine.medical_specialtyAdolescentOvariectomy03 medical and health sciencesBleomycinInternal medicineDysgerminomaovarianHumansSurvival ratechildhoodNeoplasm Stagingbusiness.industrySettore MED/20 - Chirurgia Pediatrica E InfantileInfantmedicine.diseaseSurgeryRegimen030104 developmental biologyPediatrics Perinatology and Child HealthSettore MED/20Immature teratomaGerm cell tumorsCisplatinbusinessProgressive diseaseFollow-Up StudiesPediatric bloodcancer
researchProduct